GUFICBIO · Healthcare · Drug Manufacturers - Specialty & Generic
Composite scorecard: 32/100 — Quality 45 · Valuation 0 · Momentum 53
| Share price | ₹393.75 |
| Market cap | ₹3,935 Cr |
| P/E ratio | 61.3 |
| P/B ratio | 5.9 |
| ROCE | 14.9% |
| Dividend yield | 0.03% |
| Book value | ₹66.20 |
| Year | Sales | Net profit | OPM |
|---|---|---|---|
| 2026 | ₹944 Cr | ₹64 Cr | 16.0% |
| 2025 | ₹820 Cr | ₹70 Cr | 17.0% |
| 2024 | ₹807 Cr | ₹86 Cr | 19.0% |
| 2023 | ₹680 Cr | ₹80 Cr | 17.0% |
| 2022 | — | — | — |
Gufic Biosciences Limited manufactures and markets active pharmaceutical ingredients (APIs), generic pharmaceuticals, and related services in India, Africa, Asia, Europe, Australia, North America, and South America. The company manufactures APIs and bulk drugs, such as antifungals, anaethetics, immuno suppressants, anginotensin receptor blocker, and intermediates for antifungals. It also manufactures lyophilized injections for antibiotic, antifungal, cardiac medications, infertility treatments, antiviral solutions, and proton pump inhibitors (PPIs) segments. In addition, the company offers cri